The effect of combination of glycyrrhizic acid with alpha-glutamyl-tryptophan on the experimental adenoviral infection

Cover Page


Cite item

Full Text

Abstract

In this work, the activity of glycyrrhizic acid (GL) and dipeptide alpha-glutamyl-tryptophane (EW) as single preparations or in combination (GL+EW) against experimental adenoviral infection in the syrian hamsters was studied. Application of gl and GL+EW was shown to decrease the level of the adenovirus replication in liver tissue by 0.6 – 1.2 lgTCID50 depending on the composition and time point of the post infection. It was also demonstrated that normalization of the structure of the liver tissue was required, which was shown on the level of both optical and electron microscopy. The results obtained in this work suggest that gl and GL+EW may be considered as potential component of the complex therapy of adenoviral infection.

About the authors

V. S. Smirnov

MBRD “Cytomed”

Author for correspondence.
Email: vsmirnov@cytomed.ru

Vyacheslav S. Smirnov, Doctor of Medicine, Professor, Chief Research Scientist

St. Petersburg, 191023

Россия

A. V. Slita

Influenza Research Institute

Email: fake@neicon.ru
St. Petersburg, 197376 Россия

A. V. Garshinina

Influenza Research Institute

Email: fake@neicon.ru
St. Petersburg, 197376 Россия

S. V. Belyaevskaya

Influenza Research Institute

Email: fake@neicon.ru
St. Petersburg, 197376 Россия

A. V. Anikin

Influenza Research Institute

Email: fake@neicon.ru
St. Petersburg, 197376 Россия

V. V. Zarubaev

Influenza Research Institute

Email: fake@neicon.ru
ORCID iD: 0000-0002-6837-5242
St. Petersburg, 197376 Россия

References

  1. Hierhozler J.C. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 1992; 5 (3): 262–74.
  2. Hillenkamp J., Reinhard Т., Ross R.S., Böhringer D., Cartsburg O., Roggendorf M. et al. The effect of cidofovir 1% with and without cyclosporin a 1% as а topical treatment of acute adenoviral keratoconjunctivitis: а controlled clinical pilot study. Ophtalmology. 2002; 109 (5): 845–50.
  3. Hoffman J.А., Shah А.J., Ross L.А., Kapoor N. Adenoviral infections and а prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2001; 7 (7): 388–94.
  4. Romanowski E.G., Gordon Y.J., Araullo-Cruz T., Yates K.A., Kinchington P.R. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest. Ophtalmol. Vis. Sci. 2001; 42 (8): 1812–5.
  5. Romanowski E.G., Yates K.А., Gordon Y.J. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001; 52 (3): 275–80.
  6. Safrin S., Cherrington J., Joffe H.S. Cidofovir. Review of current and potential clinical uses. Adv. Exp. Med. Biol. 1999; 458: 111–20.
  7. Gordon Y.J., Naesens L., De Clercq E., Mandel P.C., Veckeneer M. The treatment of adenoviral conjunctivitis with topical cidofovir. Cornea. 1996; 15 (5): 546.
  8. Hitchcock M.J.M., Jaffe H.S., Martin J.C., Stagg R.J. Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir. Chem. Chemother. 1996; 7 (3): 115–27.
  9. Das А., Trousdale М.D., Ren S., Lien Е.J. Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antiviral Res. 1999; 44 (3): 201–8.
  10. De Clercq Е., Sakuma Т., Baba М., Pauwels R., Balzarini J., Rosenberg I. et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Аntiviral Res. 1987; 8 (5–6): 261–72.
  11. Arav-Boger R., Echavarria М., Forman М., Charache Р., Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr. Infect. Dis. J. 2000; 19 (11): 1097–100.
  12. Shetty А.K., Gans Н.А., So S., Millan М.T., Arvin А.М., Gutierrez K.M. Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr. Pulmonol. 2000; 29 (1): 69–73.
  13. Gavin P.J., Katz B.Z. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002; 110 (1, Pt. 1): 1–8.
  14. Bordigoni Р., Carret А.S., Venard V., Witz F., Lе Faou А. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 2001; 32 (9): 1290–7.
  15. La Rosa A.M., Champlin R.Е., Mirza М., Gajewski J., Giralt S., Rolston K.V. et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin. Infect. Dis. 2001; 32 (6): 871–6.
  16. Chen F.Е., Liang R.Н., Lo J.Y., Yuen K.Y., Chan T.K., Peiris М. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997; 20 (11): 997–9.
  17. Trousdale М.D., Goldschmidt Р.L., Nobrega R. Evaluation of ganciclovir against human adenovirus type 5 infection in cell culture and cotton rat eyes. Antiviral Res. 1993; 20 (Suppl. 1): 48.
  18. Coca S., Perazella M.A. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am. J. Med. Sci. 2002; 324 (6): 342–4.
  19. Kaneko Н., Kato K., Mori S., Shigеtа S. Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res. 2001; 52 (3): 281–8.
  20. Zarubaev V.V., Slita A.V., Krivitskaya V.Z., Sirotkin A.K., Kovalenko A.L., Chatterjee N.K. Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro. Antiviral Res. 2003; 58 (2): 131–7.
  21. Rautenschlein S., Miller R.L., Sharma J.M. The inhibitory effect of the imidazoquinolinamine S-28828 on the pathogenesis of a type II adenovirus in turkeys. Antiviral Res. 2000; 46 (3): 195–205.
  22. Naesens L., Lenaerts L., Andrei G., Snoeck R., Van Beers D., Holy A. et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 2005; 49 (3): 1010–6.
  23. Mentel R., Kinder М., Wegner U., Janta-Lipinski М., Matthes Е. Inhibitory activity of 3-fluoro-2-deoxythymidine and related nucleoside analogues against adenoviruses in vitrо. Antiviral Res. 1997; 34 (3): 113–9.
  24. Alexeeva I., Dyachenko N., Nosach L., Zhovnovataya V., Rybalko S., Lozitskaya R. et al. 6-azacytidine-compound with wide spectrum of antiviral activity. Nucleosides Nucleotides Nucleic Acids. 2001; 20 (4–7): 1147–52.
  25. Zarubaev V.V., Slita A.V., Sukhinin V.P., Nosach L.N., Dyachenko N.S., Povnitsa O.Y. et al. Effect of 6-azacytidine on the course of experimental adenoviral infection in newborn Syrian hamsters. J. Chemother. 2007; 19 (1): 44–51.
  26. Dropulic L.K., Cohen J.I. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin. Pharmacol. Ther. 2010; 88 (5): 610–9.
  27. Weber J.M., Ruzindana-Umunyana A., Imbeault L., Sircar S. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res. 2003; 58 (2): 167–73.
  28. Steinmann J., Buer J., Pietschmann T., Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. 2013; 168 (5): 1059–73.
  29. Zhang Y., Schneider R.J. Adenovirus inhibition of cellular protein synthesis and the specific translation of late viral mRNAs. Semin. Virol. 1993; 4 (4): 229–36.
  30. Смирнов В.С., Зарубаев В.В., Анфимов П.М., Штро А.А. Влияние комбинации глутамил-триптофана с глицирризиновой кислотой на течение острой инфекции у мышей, вызванной вирусом гриппа (H3N2). Вопросы вирусологии. 2012; 3: 23–7.
  31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983; 65 (1–2): 55–63.
  32. Harada S., Yusa K., Monde K., Akaike T., Maeda Y. Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem. Biophys. Res. Commun. 2005; 329 (2): 480–6.
  33. Wolkerstorfer A., Kurz H., Bachhofner N., Szolar O.H. Glycyrrhizin inhibits influenza A virus uptake into the cell. Antiviral Res. 2009; 83 (2): 171–8.
  34. Fiore C., Eisenhut M., Krausse R., Ragazzi E., Pellati D., Armanini D. et al. Antiviral effects of Glycyrrhiza species. Phytother. Res. 2008; 22 (2): 141–8.
  35. Ashfaq U.A., Masoud M.S., Nawaz Z., Riazuddin S. Glycyrrhizin as antiviral agent against Hepatitis C Virus. J. Transl. Med. 2011; 9: 112.
  36. Wang J., Chen X., Wang W., Zhang Y., Yang Z., Jin Y. et al. Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease. J. Ethnopharmacol. 2013; 147 (1): 114–21.
  37. Zhang H., Song Y., Zhang Z. Glycyrrhizin administration ameliorates coxsackievirus B3-induced myocarditis in mice. Am. J. Med. Sci. 2012; 344 (3): 206–10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Smirnov V.S., Slita A.V., Garshinina A.V., Belyaevskaya S.V., Anikin A.V., Zarubaev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies